These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 11310194)
21. Effectiveness of tegaserod therapy on GI-related resource utilization in a managed care population. Stephenson JJ; Barghout V; Kahler KH; Fernandes J; Beaulieu JF; Joo S; Boccuzzi SJ Am J Manag Care; 2005 Apr; 11(1 Suppl):S35-42. PubMed ID: 15926762 [TBL] [Abstract][Full Text] [Related]
22. High frequency of use of rofecoxib at greater than recommended doses: cause for concern. Griffin MR; Stein CM; Graham DJ; Daugherty JR; Arbogast PG; Ray WA Pharmacoepidemiol Drug Saf; 2004 Jun; 13(6):339-43. PubMed ID: 15170762 [TBL] [Abstract][Full Text] [Related]
23. Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study. Moride Y; Ducruet T; Boivin JF; Moore N; Perreault S; Zhao S Arthritis Res Ther; 2005; 7(2):R333-42. PubMed ID: 15743481 [TBL] [Abstract][Full Text] [Related]
24. Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization. Sun SX; Lee KY; Bertram CT; Goldstein JL Curr Med Res Opin; 2007 Aug; 23(8):1859-66. PubMed ID: 17605893 [TBL] [Abstract][Full Text] [Related]
25. Trends and determinants of adequate gastroprotection in patients chronically using NSAIDs. Helsper CW; Smeets HM; Numans ME; Knol MJ; Hoes AW; de Wit NJ Pharmacoepidemiol Drug Saf; 2009 Sep; 18(9):800-6. PubMed ID: 19572313 [TBL] [Abstract][Full Text] [Related]
27. GI risk factors and use of GI protective agents among patients receiving nonsteroidal antiinflammatory drugs. Harris CL; Raisch DW; Abhyankar U; Marfatia S; Campbell HM; Sather MR Ann Pharmacother; 2006 Nov; 40(11):1924-31. PubMed ID: 17047140 [TBL] [Abstract][Full Text] [Related]
28. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy. Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558 [TBL] [Abstract][Full Text] [Related]
29. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors. Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791 [TBL] [Abstract][Full Text] [Related]
30. Over-the-counter nonsteroidal anti-inflammatory drugs and risk of gastrointestinal symptoms. Thomas J; Straus WL; Bloom BS Am J Gastroenterol; 2002 Sep; 97(9):2215-9. PubMed ID: 12358235 [TBL] [Abstract][Full Text] [Related]
31. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice. Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789 [TBL] [Abstract][Full Text] [Related]
32. Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: what is the potential impact of the withdrawal of rofecoxib? Rahme E; Hunsche E; Toubouti Y; Chabot I Arthritis Rheum; 2006 Feb; 55(1):27-34. PubMed ID: 16463408 [TBL] [Abstract][Full Text] [Related]
33. Gastrointestinal prophylactic therapy among patients with arthritis treated by rheumatology specialists. Garcia EB; Michaud K; Wolfe F J Rheumatol; 2006 Apr; 33(4):779-84. PubMed ID: 16511939 [TBL] [Abstract][Full Text] [Related]
34. The relationship between NSAID use and osteoarthritis (OA) severity in patients with hip and knee OA: results of a case control study of NSAID use comparing those requiring hip and knee replacements to those in whom surgery was not recommended. Pope JE; McCrea K; Stevens A; Ouimet JM Med Sci Monit; 2008 Dec; 14(12):CR604-10. PubMed ID: 19043367 [TBL] [Abstract][Full Text] [Related]
35. COX-2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors. van der Linden MW; Gaugris S; Kuipers EJ; van Herk-Sukel MP; van den Bemt BJ; Sen SS; Herings RM Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):880-90. PubMed ID: 19593747 [TBL] [Abstract][Full Text] [Related]
36. [Cost stratification of nonsteroidal anti-inflammatory drug-associated gastrointestinal side effects]. Lanas A Med Clin (Barc); 2000; 114 Suppl 3():46-53. PubMed ID: 10994564 [TBL] [Abstract][Full Text] [Related]
37. Upper gastrointestinal symptoms and therapies in elderly out-patients, users of non-selective NSAIDs or coxibs. Pilotto A; Franceschi M; Vitale DF; Zaninelli A; Masotti G; Rengo F; ; Aliment Pharmacol Ther; 2005 Jul; 22(2):147-55. PubMed ID: 16011673 [TBL] [Abstract][Full Text] [Related]
38. Safety and patient tolerance of standard and slow-release formulations of NSAIDs. Langman M; Kong SX; Zhang Q; Kahler KH; Finch E Pharmacoepidemiol Drug Saf; 2003; 12(1):61-6. PubMed ID: 12616849 [TBL] [Abstract][Full Text] [Related]
39. Rheumatologists' adherence to guidelines for misoprostol use in patients at high risk for nonsteroidal antiinflammatory drug gastropathy. Cibere J; Sibley JT; Haga M J Rheumatol; 2002 Feb; 29(2):339-46. PubMed ID: 11838854 [TBL] [Abstract][Full Text] [Related]
40. Persistency of use of COX-2-specific inhibitors and non-specific non-steroidal anti-inflammatory drugs (NSAIDs) in Quebec. Moride Y; Ducruet T; Rochon S; Lavoie F Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii17-22. PubMed ID: 14585914 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]